Aclaris Therapeutics (ACRS) Stock Forecast, Price Target & Predictions
ACRS Stock Forecast
Aclaris Therapeutics stock forecast is as follows: an average price target of $25.00 (represents a 2055.17% upside from ACRS’s last price of $1.16) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ACRS Price Target
The average price target for Aclaris Therapeutics (ACRS) is $25.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $25.00. This represents a potential 2055.17% upside from ACRS's last price of $1.16.
ACRS Analyst Ratings
According to 5 Wall Street analysts, Aclaris Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ACRS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 2 'Hold' (40.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).
Aclaris Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 01, 2022 | - | Goldman Sachs | $25.00 | $15.22 | 64.26% | 2055.17% |
The latest Aclaris Therapeutics stock forecast, released on Dec 01, 2022 by Goldman Sachs company, set a price target of $25.00, which represents a 64.26% increase from the stock price at the time of the forecast ($15.22), and a 2055.17% increase from ACRS last price ($1.16).
Aclaris Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.16 | $1.16 | $1.16 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Aclaris Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aclaris Therapeutics's last price of $1.16. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 18, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Sep 18, 2024 | BTIG | Neutral | Neutral | Hold |
| Jan 11, 2024 | Stifel Nicolaus | Buy | Buy | Hold |
| Dec 18, 2023 | H.C. Wainwright | Underperform | Underperform | Hold |
| Dec 18, 2023 | Stifel Nicolaus | Buy | Buy | Hold |
| Mar 07, 2023 | BTIG | Buy | Buy | Hold |
| Dec 01, 2022 | Goldman Sachs | - | Buy | Initialise |
| Apr 26, 2022 | Zacks Investment Research | Hold | Sell | Downgrade |
| Apr 25, 2022 | Zacks Investment Research | - | Hold | Downgrade |
Aclaris Therapeutics's last stock rating was published by H.C. Wainwright on Sep 18, 2024. The company gave ACRS a "Neutral" rating, the same as its previous rate.
Aclaris Therapeutics Financial Forecast
Aclaris Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $17.57M | $9.28M | $1.87M | $2.53M | $7.75M | $19.02M | $1.53M | $1.45M | $1.50M | $1.66M | $1.82M | $1.78M | $1.58M | $1.45M | $2.05M | $1.41M | $1.09M | $983.00K | $5.87M | $5.04M | $1.12M |
| Avg Forecast | $3.10M | $2.97M | $2.84M | $2.77M | $2.17M | $1.57M | $1.82M | $1.93M | $4.66M | $1.57M | $1.90M | $1.75M | $1.99M | $1.60M | $1.61M | $1.60M | $1.79M | $1.77M | $1.75M | $1.48M | $1.39M | $1.47M | $1.23M | $1.13M | $9.80M | $5.92M | $5.55M | $4.81M | $1.14M |
| High Forecast | $3.10M | $2.97M | $2.84M | $2.77M | $2.17M | $6.13M | $1.82M | $1.93M | $11.32M | $1.57M | $1.90M | $1.75M | $1.99M | $1.60M | $1.61M | $1.60M | $1.79M | $1.77M | $1.75M | $1.48M | $1.39M | $1.47M | $1.23M | $1.13M | $9.80M | $5.92M | $5.55M | $4.81M | $1.37M |
| Low Forecast | $3.10M | $2.97M | $2.84M | $2.77M | $2.17M | $139.95K | $1.82M | $1.93M | $834.83K | $1.57M | $1.90M | $1.75M | $1.99M | $1.60M | $1.61M | $1.60M | $1.79M | $1.77M | $1.75M | $1.48M | $1.39M | $1.47M | $1.23M | $1.13M | $9.80M | $5.92M | $5.55M | $4.81M | $912.65K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | 3.77% | 5.90% | 0.98% | 1.45% | 3.89% | 11.88% | 0.95% | 0.91% | 0.84% | 0.94% | 1.04% | 1.20% | 1.14% | 0.99% | 1.67% | 1.25% | 0.11% | 0.17% | 1.06% | 1.05% | 0.98% |
Aclaris Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $1.93M, with a low forecast of $1.93M, and a high forecast of $1.93M. ACRS's average Quarter revenue forecast represents a -89.02% decrease compared to the company's last Quarter revenue of $17.57M (Dec 23).
Aclaris Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | $-4.05M | $-31.58M | $-31.82M | $-31.32M | $-14.88M | $-16.28M | $-27.59M | $-21.10M | $-22.61M | $-20.95M | $-17.91M | $-28.47M | $-13.80M | $-10.07M | $-10.99M | $-15.01M | $-18.27M | $-53.69M | $-47.65M | $-35.34M | $-30.01M |
| Avg Forecast | $-3.10M | $-2.97M | $-2.84M | $-2.77M | $-2.17M | $-1.57M | $-1.82M | $-27.54M | $-4.66M | $-1.57M | $-1.90M | $-25.04M | $-1.99M | $-1.60M | $-1.61M | $-22.76M | $-1.79M | $-1.77M | $-1.75M | $-27.65M | $-1.39M | $-1.47M | $-1.23M | $-12.66M | $-9.80M | $-5.92M | $-5.55M | $-30.48M | $-30.61M |
| High Forecast | $-3.10M | $-2.97M | $-2.84M | $-2.77M | $-2.17M | $-139.95K | $-1.82M | $-22.03M | $-834.83K | $-1.57M | $-1.90M | $-20.03M | $-1.99M | $-1.60M | $-1.61M | $-18.21M | $-1.79M | $-1.77M | $-1.75M | $-22.12M | $-1.39M | $-1.47M | $-1.23M | $-10.13M | $-9.80M | $-5.92M | $-5.55M | $-24.38M | $-24.49M |
| Low Forecast | $-3.10M | $-2.97M | $-2.84M | $-2.77M | $-2.17M | $-6.13M | $-1.82M | $-33.05M | $-11.32M | $-1.57M | $-1.90M | $-30.05M | $-1.99M | $-1.60M | $-1.61M | $-27.31M | $-1.79M | $-1.77M | $-1.75M | $-33.18M | $-1.39M | $-1.47M | $-1.23M | $-15.20M | $-9.80M | $-5.92M | $-5.55M | $-36.58M | $-36.73M |
| Surprise % | - | - | - | - | - | - | - | - | 0.87% | 20.07% | 16.75% | 1.25% | 7.46% | 10.17% | 17.12% | 0.93% | 12.62% | 11.83% | 10.26% | 1.03% | 9.93% | 6.85% | 8.95% | 1.19% | 1.86% | 9.06% | 8.59% | 1.16% | 0.98% |
undefined analysts predict ACRS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aclaris Therapeutics's previous annual EBITDA (undefined) of $NaN.
Aclaris Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| Net Income | - | - | - | - | - | - | - | - | $-1.49M | $-29.26M | $-29.57M | $-26.40M | $-33.29M | $-21.23M | $-16.67M | $-17.47M | $-22.80M | $-21.15M | $-18.16M | $-28.75M | $-13.17M | $-10.66M | $-11.60M | $-15.59M | $-18.59M | $-55.32M | $-49.88M | $-37.56M | $-30.23M |
| Avg Forecast | $-12.12M | $-11.41M | $-11.76M | $-11.41M | $-11.20M | $-407.36K | $-14.59M | $-27.85M | $-24.56M | $-34.21M | $-32.09M | $-25.32M | $-31.75M | $-27.89M | $-25.55M | $-23.02M | $-26.02M | $-20.08M | $-19.61M | $-27.93M | $-21.92M | $-22.28M | $-25.31M | $-13.15M | $-2.50M | $-49.19M | $-54.00M | $-32.40M | $-30.83M |
| High Forecast | $-12.12M | $-11.41M | $-11.76M | $-11.41M | $-11.20M | $1.22M | $-14.59M | $-22.28M | $-11.95M | $-34.21M | $-32.09M | $-20.25M | $-31.75M | $-27.89M | $-25.55M | $-18.41M | $-26.02M | $-20.08M | $-19.61M | $-22.34M | $-21.92M | $-22.28M | $-25.31M | $-10.52M | $-2.50M | $-49.19M | $-54.00M | $-25.92M | $-24.67M |
| Low Forecast | $-12.12M | $-11.41M | $-11.76M | $-11.41M | $-11.20M | $-916.56K | $-14.59M | $-33.42M | $-28.54M | $-34.21M | $-32.09M | $-30.38M | $-31.75M | $-27.89M | $-25.55M | $-27.62M | $-26.02M | $-20.08M | $-19.61M | $-33.52M | $-21.92M | $-22.28M | $-25.31M | $-15.78M | $-2.50M | $-49.19M | $-54.00M | $-38.88M | $-37.00M |
| Surprise % | - | - | - | - | - | - | - | - | 0.06% | 0.86% | 0.92% | 1.04% | 1.05% | 0.76% | 0.65% | 0.76% | 0.88% | 1.05% | 0.93% | 1.03% | 0.60% | 0.48% | 0.46% | 1.19% | 7.45% | 1.12% | 0.92% | 1.16% | 0.98% |
Aclaris Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ACRS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Aclaris Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| SG&A | - | - | - | - | - | - | - | - | $3.30M | $7.09M | $8.32M | $8.79M | $7.15M | $5.81M | $6.08M | $6.10M | $6.94M | $5.98M | $5.87M | $4.83M | $4.90M | $3.86M | $5.57M | $6.20M | $6.61M | $6.29M | $15.17M | $18.02M | $17.49M |
| Avg Forecast | $9.35M | $8.95M | $8.57M | $8.35M | $6.54M | $4.75M | $5.48M | $5.82M | $14.05M | $4.75M | $5.73M | $5.27M | $6.02M | $4.83M | $4.86M | $4.82M | $5.40M | $5.34M | $5.27M | $4.47M | $4.19M | $4.43M | $3.71M | $3.39M | $29.57M | $17.87M | $16.73M | $14.52M | $3.44M |
| High Forecast | $9.35M | $8.95M | $8.57M | $8.35M | $6.54M | $18.50M | $5.48M | $5.82M | $34.16M | $4.75M | $5.73M | $5.27M | $6.02M | $4.83M | $4.86M | $4.82M | $5.40M | $5.34M | $5.27M | $4.47M | $4.19M | $4.43M | $3.71M | $3.39M | $29.57M | $17.87M | $16.73M | $14.52M | $4.13M |
| Low Forecast | $9.35M | $8.95M | $8.57M | $8.35M | $6.54M | $422.19K | $5.48M | $5.82M | $2.52M | $4.75M | $5.73M | $5.27M | $6.02M | $4.83M | $4.86M | $4.82M | $5.40M | $5.34M | $5.27M | $4.47M | $4.19M | $4.43M | $3.71M | $3.39M | $29.57M | $17.87M | $16.73M | $14.52M | $2.75M |
| Surprise % | - | - | - | - | - | - | - | - | 0.23% | 1.49% | 1.45% | 1.67% | 1.19% | 1.20% | 1.25% | 1.26% | 1.28% | 1.12% | 1.11% | 1.08% | 1.17% | 0.87% | 1.50% | 1.83% | 0.22% | 0.35% | 0.91% | 1.24% | 5.08% |
Aclaris Therapeutics's average Quarter SG&A projection for Mar 24 is $5.82M, based on 4 Wall Street analysts, with a range of $5.82M to $5.82M. The forecast indicates a 76.53% rise compared to ACRS last annual SG&A of $3.30M (Dec 23).
Aclaris Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.39 | $-0.50 | $-0.32 | $-0.25 | $-0.28 | $-0.37 | $-0.35 | $-0.34 | $-0.57 | $-0.30 | $-0.25 | $-0.28 | $-0.37 | $-0.45 | $-1.34 | $-1.21 | $-0.91 | $-0.98 |
| Avg Forecast | $-0.17 | $-0.16 | $-0.17 | $-0.16 | $-0.16 | $-0.01 | $-0.20 | $-0.29 | $-0.34 | $-0.48 | $-0.45 | $-0.44 | $-0.45 | $-0.39 | $-0.36 | $-0.39 | $-0.36 | $-0.28 | $-0.28 | $-0.30 | $-0.31 | $-0.31 | $-0.35 | $-0.38 | $-0.04 | $-0.69 | $-0.76 | $-0.80 | $-1.02 |
| High Forecast | $-0.17 | $-0.16 | $-0.17 | $-0.16 | $-0.16 | $0.02 | $-0.20 | $-0.29 | $-0.17 | $-0.48 | $-0.45 | $-0.44 | $-0.45 | $-0.39 | $-0.36 | $-0.39 | $-0.36 | $-0.28 | $-0.28 | $-0.30 | $-0.31 | $-0.31 | $-0.35 | $-0.38 | $-0.04 | $-0.69 | $-0.76 | $-0.80 | $-0.82 |
| Low Forecast | $-0.17 | $-0.16 | $-0.17 | $-0.16 | $-0.16 | $-0.01 | $-0.20 | $-0.29 | $-0.40 | $-0.48 | $-0.45 | $-0.44 | $-0.45 | $-0.39 | $-0.36 | $-0.39 | $-0.36 | $-0.28 | $-0.28 | $-0.30 | $-0.31 | $-0.31 | $-0.35 | $-0.38 | $-0.04 | $-0.69 | $-0.76 | $-0.80 | $-1.22 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.89% | 1.12% | 0.82% | 0.70% | 0.71% | 1.01% | 1.24% | 1.24% | 1.87% | 0.98% | 0.80% | 0.79% | 0.99% | 12.86% | 1.94% | 1.60% | 1.13% | 0.96% |
According to undefined Wall Street analysts, Aclaris Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ACRS previous annual EPS of $NaN (undefined).
Aclaris Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics | $1.17 | $25.00 | 2036.75% | Buy |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| BDSX | Biodesix | $1.63 | $3.00 | 84.05% | Buy |
| MYGN | Myriad Genetics | $23.33 | $29.00 | 24.30% | Hold |
| MEDP | Medpace | $342.89 | $423.20 | 23.42% | Hold |
| CSTL | Castle Biosciences | $33.06 | $40.50 | 22.50% | Buy |
| QGEN | Qiagen | $42.69 | $51.89 | 21.55% | Buy |
| NEOG | Neogen | $14.46 | $17.50 | 21.02% | Buy |
| IQV | IQVIA | $233.89 | $270.35 | 15.59% | Buy |
| SHC | Sotera Health Company | $15.77 | $16.93 | 7.36% | Buy |
| ICLR | ICON Public Limited Company | $295.24 | $316.70 | 7.27% | Buy |
| RDNT | RadNet | $68.36 | $69.00 | 0.94% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
ACRS Forecast FAQ
Is Aclaris Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Aclaris Therapeutics (ACRS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of ACRS's total ratings.
What is ACRS's price target?
Aclaris Therapeutics (ACRS) average price target is $25 with a range of $25 to $25, implying a 2055.17% from its last price of $1.16. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Aclaris Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ACRS stock, the company can go up by 2055.17% (from the last price of $1.16 to the average price target of $25), up by 2055.17% based on the highest stock price target, and up by 2055.17% based on the lowest stock price target.
Can Aclaris Therapeutics stock reach $2?
ACRS's average twelve months analyst stock price target of $25 supports the claim that Aclaris Therapeutics can reach $2 in the near future.
What are Aclaris Therapeutics's analysts' financial forecasts?
Aclaris Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $7.49M (high $12.04M, low $6.05M), average EBITDA is $-33.1M (high $-26.157M, low $-43.165M), average net income is $-54.053M (high $-46.854M, low $-60.133M), average SG&A $22.59M (high $36.33M, low $18.26M), and average EPS is $-0.653 (high $-0.63, low $-0.66). ACRS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $11.67M (high $11.67M, low $11.67M), average EBITDA is $-11.675M (high $-11.675M, low $-11.675M), average net income is $-46.696M (high $-46.696M, low $-46.696M), average SG&A $35.22M (high $35.22M, low $35.22M), and average EPS is $-0.655 (high $-0.655, low $-0.655).
Did the ACRS's actual financial results beat the analysts' financial forecasts?
Based on Aclaris Therapeutics's last annual report (Dec 2023), the company's revenue was $31.25M, beating the average analysts forecast of $9.88M by 216.36%. Apple's EBITDA was $-97.357M, beating the average prediction of $-33.167M by 193.53%. The company's net income was $-88.481M, missing the average estimation of $-116M by -23.83%. Apple's SG&A was $32.41M, beating the average forecast of $29.8M by 8.77%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.711 by -99.92%. In terms of the last quarterly report (Dec 2023), Aclaris Therapeutics's revenue was $17.57M, beating the average analysts' forecast of $4.66M by 277.34%. The company's EBITDA was $-4.047M, missing the average prediction of $-4.656M by -13.08%. Aclaris Therapeutics's net income was $-1.491M, missing the average estimation of $-24.556M by -93.93%. The company's SG&A was $3.3M, missing the average forecast of $14.05M by -76.54%. Lastly, the company's EPS was $0, missing the average prediction of $-0.344 by -100.00%